WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005035001) SUSTAINED RELEASE L-ARGININE FORMULATIONS AND METHODS OF MANUFACTURE AND USE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/035001 International Application No.: PCT/US2004/013255
Publication Date: 21.04.2005 International Filing Date: 28.04.2004
IPC:
A61K 47/32 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
32
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
Applicants: RON, Eyal, S.[US/US]; US (UsOnly)
ENOS PHARMACEUTICALS, INC.[US/US]; One Canal Park Cambridge, MA 02141, US (AllExceptUS)
Inventors: RON, Eyal, S.; US
Agent: SMITH, DeAnn, F. ; Foley Hoag LLP Seaport World Trade Center West 155 Seaport Boulevard Boston, MA 02210-1450, US
Priority Data:
60/507,31229.09.2003US
60/512,03517.10.2003US
PCT/US03/03393124.10.2003US
Title (EN) SUSTAINED RELEASE L-ARGININE FORMULATIONS AND METHODS OF MANUFACTURE AND USE
(FR) FORMULATIONS DE L'ARGININE A LIBERATION PROLONGEE, PROCEDES DE FABRICATION ET UTILISATIONS
Abstract:
(EN) The present invention provides methods and formulations for the treatment and prevention of cerebrovascular and cardiovascular diseases and disorders. The present invention is based, at least in part, on the discovery that administering to a subject a formulation comprising an agonist of endothelial nitric oxide synthase (eNOS), such as an HMG-CoA reductase inhibitor, and a formulation comprising a precursor of NO, such as L-arginine, may be used to treat or prevent cerebrovascular and/or cardiovascular diseases or disorders.
(FR) L'invention concerne des procédés et des formulations pour le traitement et la prévention de maladies et troubles cérébrovasculaires et cardiovasculaires. L'invention est basée, au moins partiellement, sur la découverte reposant sur le fait que l'administration à un sujet, d'une formulation comprenant un agoniste de synthase d'oxyde nitrique endothélial (eNOS), tel qu'un inhibiteur de réductase de HMG-CoA, et d'une formulation comprenant un précurseur de NO, tel que la L-arginine, peut être utilisée pour le traitement ou la prévention de maladies ou de troubles cérébrovasculaires et/ou cardiovasculaires.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)